Share-based Payment Arrangement, Expense of Bionik Laboratories Corp. from 31 Mar 2013 to 31 Mar 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Bionik Laboratories Corp. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2013 to 31 Mar 2023.
  • Bionik Laboratories Corp. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2023 was $114,000, a 42% increase year-over-year.
  • Bionik Laboratories Corp. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2023 was $300,000, a 25% decline year-over-year.
  • Bionik Laboratories Corp. annual Share-based Payment Arrangement, Expense for 2022 was $300,000, a 25% decline from 2021.
  • Bionik Laboratories Corp. annual Share-based Payment Arrangement, Expense for 2021 was $400,000, a 50% decline from 2020.
  • Bionik Laboratories Corp. annual Share-based Payment Arrangement, Expense for 2020 was $800,000, a 53% decline from 2019.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Bionik Laboratories Corp. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2023 $300,000 $114,000 +$34,000 +42% 01 Jan 2023 31 Mar 2023 10-K 21 Jun 2023 2023 FY
Q4 2022 $266,000 $31,000 -$169,000 -84% 01 Oct 2022 31 Dec 2022 10-Q 08 Feb 2023 2023 Q3
Q3 2022 $435,000 $55,000 +$35,000 +175% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2022 2023 Q2
Q2 2022 $400,000 $100,000 $0 0% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2022 2022 Q1
Q1 2022 $400,000 $80,000 -$20,000 -20% 01 Jan 2022 31 Mar 2022 10-K 21 Jun 2023 2023 FY
Q4 2021 $420,000 $200,000 +$100,000 +100% 01 Oct 2021 31 Dec 2021 10-Q 08 Feb 2023 2023 Q3
Q3 2021 $320,000 $20,000 -$180,000 -90% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2023 Q2
Q2 2021 $500,000 $100,000 -$300,000 -75% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q1
Q1 2021 $800,000 $100,000 -$1,098,140 -92% 01 Jan 2021 31 Mar 2021 10-K 09 Jun 2022 2022 FY
Q4 2020 $1,898,140 $100,000 -$347,000 -78% 01 Oct 2020 31 Dec 2020 10-Q 09 Feb 2022 2022 Q3
Q3 2020 $2,245,140 $200,000 +$173,694 +660% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2022 Q2
Q2 2020 $2,071,446 $400,000 +$371,446 +1301% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2022 Q1
Q1 2020 $1,700,000 $1,198,140 +$1,169,212 +4042% 01 Jan 2020 31 Mar 2020 10-K 24 Jun 2021 2021 FY
Q4 2019 $530,788 $447,000 +$412,357 +1190% 01 Oct 2019 31 Dec 2019 10-Q 11 Feb 2021 2020 Q3
Q3 2019 $118,431 $26,306 -$10,960 -29% 01 Jul 2019 30 Sep 2019 10-Q 14 Nov 2019 2019 Q2
Q2 2019 $129,391 $28,554 -$11,149 -28% 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2019 2019 Q1
Q1 2019 $140,540 $28,928 01 Jan 2019 31 Mar 2019 10-K 29 Jun 2020 2020 FY
Q4 2018 $34,643 -$5,060 -13% 01 Oct 2018 31 Dec 2018 10-Q 11 Feb 2019 2019 Q3
Q3 2018 $37,266 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019 2019 Q2
Q2 2018 $39,703 01 Apr 2018 30 Jun 2018 10-Q 12 Aug 2019 2019 Q1
Q2 2018 $562 01 Jun 2018 11 Jun 2018 10-Q 14 Aug 2018 2019 Q1
Q4 2017 $39,703 01 Jan 2018 24 Jan 2018 10-Q 14 Aug 2018 2019 Q1

Bionik Laboratories Corp. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $300,000 -$100,000 -25% 01 Apr 2022 31 Mar 2023 10-K 21 Jun 2023 2023 FY
2021 $400,000 -$400,000 -50% 01 Apr 2021 31 Mar 2022 10-K 21 Jun 2023 2023 FY
2020 $800,000 -$900,000 -53% 01 Apr 2020 31 Mar 2021 10-K 09 Jun 2022 2022 FY
2019 $1,700,000 +$1,559,460 +1110% 01 Apr 2019 31 Mar 2020 10-K 24 Jun 2021 2021 FY
2018 $140,540 +$113,260 +415% 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020 2020 FY
2017 $27,280 01 Apr 2017 31 Mar 2018 10-K 01 Jul 2019 2019 FY
2013 $0 -$117,192 -100% 01 Apr 2013 31 Mar 2014 10-KT 27 May 2015 2014 FY
2012 $117,192 01 Apr 2012 31 Mar 2013 10-KT 27 May 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.